Evaluating The Clinical Significance Of Serum He4 Levels In Lung Cancer And Pulmonary Tuberculosis

W Liu,J Yang,P-D Chi,X Zheng,S-Q Dai,H Chen,B-L Xu,W-L Liu
DOI: https://doi.org/10.5588/ijtld.13.0058
2013-01-01
Abstract:OBJECTIVE: To evaluate whether serum human epididymis protein 4 (HE4) levels could be used as a marker to differentiate lung cancer from pulmonary tuberculosis (PTB) and as a prognostic indicator in patients with non-small-cell lung cancer (NSCLC). DESIGN: HE4 levels were measured in serum samples from 106 healthy controls, 190 lung cancer patients, 114 patients with PTB and 24 patients with pneumonia using enzyme-linked immunosorbent assay. RESULTS: Serum HE4 levels in lung cancer patients were significantly higher than those in patients with PTB and healthy controls (P < 0.001). Using the optimal cut-off value of 94.01 pmol/1, HE4 levels distinguished lung cancer from PTB with a sensitivity of 61.6% and a specificity of 93.0%. After adjusting for age and smoking status, a binary unconditional logistic regression model provided a sensitivity of 67.4% and a specificity of 86.0% for differentiating between these two diseases. In the NSCLC group, serum HE4 levels were significantly higher in patients at advanced stages (Stage I-II vs. Stage III-IV, P = 0.02). Higher levels of serum HE4 (83.90 pmol/1) were significantly correlated with a worse 3-year survival rate for patients with NSCLC (P < 0.05). CONCLUSION: Serum HE4 may be used as a potential marker to differentiate lung cancer from PTB and healthy controls. In addition, higher levels of HE4 predict poor prognosis in NSCLC patients.
What problem does this paper attempt to address?